Company profile: First Wave BioPharma
1.1 - Company Overview
Company description
- Provider of medical solutions for gastrointestinal diseases, focused on Inflammatory Bowel Disease. Offerings include a gut-restricted small molecule for oral or rectal administration to treat ulcerative colitis and other IBDs, and a pipeline comprising latiglutenase to aid gluten digestion in celiac disease, capeserod (a selective 5-HT4 partial agonist) being developed for gastroparesis, and adrulipase for exocrine pancreatic insufficiency.
Products and services
- Adrulipase: A recombinant lipase for treating exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis
- Capeserod: A selective 5-HT4 receptor partial agonist being developed for gastroparesis and potentially other GI disorders
- Latiglutenase: An oral biotherapeutic for aiding gluten digestion and potentially reducing symptoms of celiac disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to First Wave BioPharma
SafeHeal
HQ: France
Website
- Description: Provider of Colovac, an innovative colorectal anastomosis protection device designed to reduce contact of fecal content at the anastomotic site following colorectal surgery, intended to eliminate the need for a diverting ostomy and reduce anastomotic complications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SafeHeal company profile →
Functional Gut Diagnostics
HQ: United Kingdom
Website
- Description: Provider of cutting-edge technology, test kits, and analysis for gut health, enabling healthcare providers to gather critical clinical data to aid diagnosis and treatment decisions, while improving performance, delivery, analytical power, and diagnostic test assistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Functional Gut Diagnostics company profile →
Norgine
HQ: The Netherlands
Website
- Description: Provider of specialist pharmaceuticals with direct commercial presence in major European markets and infrastructure to develop, manufacture and commercialise therapies, including MOVICOL for chronic constipation; MOVIPREP and PLENVU for colon cleansing before colonoscopy; XIFAXAN for hepatic encephalopathy; FERACCRU for iron deficiency anemia; and LYMPHOSEEK for lymphatic mapping and sentinel lymph node biopsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Norgine company profile →
Protagonist Therapeutics
HQ: Australia
Website
- Description: Provider of orally-stable peptide therapeutics to treat diseases currently addressed by injectable antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protagonist Therapeutics company profile →
Terns Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical drug discovery and development targeting NASH, obesity, and chronic myeloid leukemia, with a pipeline including TERN-501 (THRβ agonist) and liver-distributed TERN-101 (FXR agonist) for NASH; TERN-701 (allosteric BCR-ABL inhibitor) for CML; TERN-601 (oral GLP-1 agonist) and TERN-800 (GIP modulators, IND-enabling in 2024) for obesity; and TERN-201 (selective VAP-1 inhibitor) for NASH.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Terns Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for First Wave BioPharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to First Wave BioPharma
2.2 - Growth funds investing in similar companies to First Wave BioPharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for First Wave BioPharma
4.2 - Public trading comparable groups for First Wave BioPharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →